The Vanguard Group 13D and 13G filings for Kiniksa Pharmaceuticals, Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:07 pm Sale | 2023-12-29 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | The Vanguard Group | 2,965,299 8.370% | -261,592 (-8.11%) | Filing |
| 2023-02-09 11:25 am Purchase | 2022-12-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | The Vanguard Group | 3,226,891 9.340% | 336,183 (+11.63%) | Filing |
| 2022-02-10 08:22 am Purchase | 2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | The Vanguard Group | 2,890,708 8.530% | 354,287 (+13.97%) | Filing |
| 2021-02-10 11:10 am Purchase | 2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | The Vanguard Group | 2,536,421 8.020% | 1,334,968 (+111.11%) | Filing |
| 2020-02-12 11:13 am Purchase | 2019-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | The Vanguard Group | 1,201,453 6.260% | 293,180 (+32.28%) | Filing |